This new deal covers the following territories:
“We are delighted about this new partnership at IMCD Business Group Pharmaceuticals, as this is the first time IMCD has an agency for an API manufacturer in Australia and New Zealand,” comments Anne-Claire Bizet, IMCD European API Development Manager. “APIs are a great complement to our comprehensive excipient portfolio which makes our offer to the pharmaceutical market complete.”
Milan-based, FIS has custom synthesis as their core business, thus having the exclusive production of intermediates, advanced intermediates and APIs for leading pharmaceutical companies. FIS provides a wide array of integrated services to the customer, including process research and development, optimisation, and scale-up facilities to support both validation and commercial launch.
IMCD Pharmaceutical Business Group is the number one distributor of pharmaceutical ingredients in Europe, supplying a comprehensive range of excipients, active ingredients, speciality solvents, process chemicals and intermediates. IMCD's team of high-calibre pharmacists across the Group work closely with principal partners to provide expert formulation support and advice, focusing on key project development to deliver innovative solutions. Furthermore, IMCD's commitment to conduct regular seminars ensures that all customer requirements are met and target objectives can be agreed upon.